NCT02668666 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02668666
Title	Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Oana Danciu, MD
Indications	Her2-receptor negative breast cancer
Therapies	Palbociclib + Tamoxifen
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 7 of 7 entries

Facility	City	State	Zip	Country	Details
Michigan State University	Lansing	Michigan	48910	United States	Details
Penn State Cancer Institute	Hershey	Pennsylvania	17033	United States	Details
ProHealth Care	Waukesha	Wisconsin	53188	United States	Details
University of Illinois Cancer Center	Chicago	Illinois	60612	United States	Details
University of Minnesota	Minneapolis	Minnesota	55455	United States	Details
University of Nebraska Medical Center	Omaha	Nebraska	68198	United States	Details
University of Wisconsin	Madison	Wisconsin	53705	United States	Details

Showing 1 to 7 of 7 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT02668666Clinical Trial Detail